Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 14.
doi: 10.1007/s12015-024-10783-7. Online ahead of print.

Submission to Stem Cells Reviews and Reports

Rubén Escribá  1 , Meral Beksac  2 , Annelise Bennaceur-Griscelli  3 , Joel C Glover  4 , Satu Koskela  5 , Helen Latsoudis  6   7 , Sergi Querol  1 , Belén Alvarez-Palomo  8
Affiliations
Review

Submission to Stem Cells Reviews and Reports

Rubén Escribá et al. Stem Cell Rev Rep. .

Abstract

The use of allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies for regenerative medicine offers an affordable and realistic alternative to producing individual iPSC lines for each patient in need. Human Leukocyte Antigens (HLA)-homozygous iPSCs matched in hemi-similarity could provide cell therapies with reduced immune rejection covering a wide range of the population with a few iPSC lines. Several banks of HLA-homozygous iPSCs (haplobanks) have been established worldwide or are underway, to provide clinical grade starting material for cell therapies covering the most frequent HLA haplotypes for certain populations. Harmonizing quality standards among haplobanks and creating a global registry could minimize the collective effort and provide a much wider access to HLA-compatible cell therapies for patients with less frequent haplotypes. In this review we present all the current haplobank initiatives and their potential benefits for the global population.

Keywords: HLA-homozygous; HLA-match; Haplobanks; Induced pluripotent stem cells; Regenerative medicine.

PubMed Disclaimer

References

    1. Yamanaka, S. (2020). Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell, 27(4), 523–531. https://doi.org/10.1016/j.stem.2020.09.014 - DOI - PubMed
    1. Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., Terada, M., Nomiya, Y., Tanishima, S., Nakamura, M., Kamao, H., Sugita, S., Onishi, A., Ito, T., Fujita, K., … Takahashi, M. (2017). Autologous induced stem-cell-derived retinal cells for macular degeneration. New England Journal of Medicine, 376(11), 1038–1046. https://doi.org/10.1056/NEJMoa1608368 - DOI - PubMed
    1. Garber, K. (2015). RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nature Biotechnology, 33, 890–891. https://doi.org/10.1038/nbt0915-890 - DOI - PubMed
    1. Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., … Takahashi, M. (2020). HLA-matched allogeneic iPS cells-derived RPE transplantation for macular degeneration. Journal of Clinical Medicine, 9(7), 2217. https://doi.org/10.3390/jcm9072217 - DOI - PubMed - PMC
    1. Kim, J. Y., Nam, Y., Rim, Y. A., & Ju, J. H. (2022). Review of the current trends in clinical trials involving induced pluripotent stem cells. Stem Cell Reviews and Reports, 18(1), 142–154. https://doi.org/10.1007/s12015-021-10262-3 - DOI - PubMed

LinkOut - more resources